Published in Gastrointest Cancer Res on January 01, 2012
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol (2009) 5.11
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med (2010) 4.13
Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol (1996) 3.23
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer (2008) 1.57
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer (2006) 1.41
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology (2004) 1.12
Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol (2008) 1.02
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer (2010) 1.00
Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin Pathol (2008) 0.99
Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol (2001) 0.98
Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery (2010) 0.96
The clear cell variant of solid pseudopapillary tumor of the pancreas: a previously unrecognized pancreatic neoplasm. Am J Surg Pathol (2006) 0.95
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol (2010) 0.86
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.11
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol (2007) 1.84
A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther (2008) 1.64
Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg (2013) 1.57
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer (2011) 1.53
The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest Endosc (2007) 1.53
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther (2008) 1.52
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist (2011) 1.44
An uncommon cause of life-threatening gastrointestinal bleeding: 2 synchronous Dieulafoy lesions. J Pediatr Surg (2009) 1.36
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc (2007) 1.35
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) (2010) 1.30
Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol (2007) 1.29
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013) 1.24
Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist (2011) 1.20
Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol (2012) 1.20
Breast cancer in low- and middle-income countries: an emerging and challenging epidemic. J Oncol (2010) 1.20
Inflammatory pseudo-tumor of the liver: a rare pathological entity. World J Surg Oncol (2011) 1.19
Update on totally implantable venous access devices. Surg Oncol (2012) 1.17
Isolated splenic metastasis from colorectal cancer. Int J Clin Oncol (2011) 1.16
A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One (2012) 1.15
Summary of NIH Medical-Surgical Emergency Research Roundtable held on April 30 to May 1, 2009. Ann Emerg Med (2010) 1.14
A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients. J Palliat Med (2013) 1.14
Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res (2005) 1.13
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res (2013) 1.13
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer (2010) 1.12
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res (2008) 1.12
Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck (2008) 1.11
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev (2014) 1.11
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist (2010) 1.10
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res (2011) 1.10
Secondary bile acids: an underrecognized cause of colon cancer. World J Surg Oncol (2014) 1.07
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab (2005) 1.07
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer (2011) 1.05
Costs and trends in pancreatic cancer treatment. Cancer (2012) 1.04
Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res (2008) 1.04
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study. Cancer (2012) 1.04
Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol (2012) 1.02
Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol (2006) 1.01
Sorghum expressed sequence tags identify signature genes for drought, pathogenesis, and skotomorphogenesis from a milestone set of 16,801 unique transcripts. Plant Physiol (2005) 0.98
Auxiliary liver transplantation for acute liver failure in children. Ann Surg (2010) 0.98
Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol (2003) 0.98
Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med (2010) 0.98
Primary undifferentiated embryonal sarcoma of the liver mistaken for hydatid disease. World J Surg Oncol (2010) 0.98
Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018. Popul Health Metr (2014) 0.97
Unusually young age distribution of primary hepatic leiomyosarcoma: case series and review of the adult literature. World J Surg Oncol (2010) 0.97
Spontaneous complete regression of hepatic epithelioid haemangioendothelioma. Lancet Oncol (2006) 0.95
Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol (2010) 0.95
Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol (2010) 0.94
Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol (2014) 0.93
Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol (2013) 0.93
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg (2014) 0.92
Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol (2011) 0.92
Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer (2011) 0.92
Refinement of adjuvant therapy for pancreatic cancer. JAMA (2010) 0.92
Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin (2002) 0.92
Thyroid cancer outcomes in Filipino patients. Arch Otolaryngol Head Neck Surg (2010) 0.92
Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother (2005) 0.91
Personality traits predict emergency department utilization over 3 years in older patients. Am J Geriatr Psychiatry (2009) 0.91
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology (2009) 0.90
Postoperative outcomes after laparoscopic splenectomy compared with open splenectomy. Ann Surg (2013) 0.90
Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis. Clin Colorectal Cancer (2008) 0.90
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. Radiat Oncol (2010) 0.90
A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg (2016) 0.90
Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89
Maxillary Sinus Squamous Cell Carcinoma Presenting with Fatal Tumor Lysis Syndrome: A Case Report and Review of the Literature. Case Rep Oncol (2009) 0.89
Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol (2004) 0.89
Voice outcomes from subligamentous cordectomy for early glottic cancer. Ann Otol Rhinol Laryngol (2013) 0.89
Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer (2014) 0.88
Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice? World J Surg Oncol (2013) 0.88